Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

New Protein Discovery Could Lead to New HIV Drugs

February 6, 2012

New Protein Discovery Could Lead to New HIV Drugs

A team of researchers at the Johns Hopkins Bloomberg School of Public Health recently discovered a new protein that enables HIV to destroy human cells. The discovery provides scientists with an important look into the complex interactions between HIV proteins and human proteins, an understanding that could potentially lead to new HIV drug therapies. The study was published in the January 19, issue of Nature.

HIV is a small pathogen that includes about 15 proteins which can act in various combinations with the more than 30,000 proteins in human cells. APOBEC3G is a human protein that has the power to mutate HIV's genome and prevent infection. However, an HIV protein called HIV-1 viral infectivity factor (Vif) typically degrades APOBEC3G before it can do its job.

Focusing on the interaction between Vif and APOBEC3G, the study researchers found that another protein called CBF-ß was a key factor necessary for the degradation of APOBEC3G to take place.

"I've been working in this field for over 25 years and I am certain that there is still even more left to this story," explained Xiao-Fang Yu, M.D., D.Sc., professor in the Bloomberg School's W. Harry Feinstone Department of Molecular Microbiology and Immunology and lead author of the study. "This is an exciting time to be in HIV research."

"The identification of CBF-ß is only one piece of the puzzle, but it's an important one," said Sean L. Evans, a Ph.D. candidate in the Department of Molecular Microbiology and Immunology and an author of the study. "The human protein APOBEC3G is designed to weaken HIV, and the virus has evolved a mechanism for defeating this anti-viral factor."

The next step, now that scientists have identified CBF-ß, will be to test various inhibitors and potential drug therapies to determine which ones disrupt the interaction between CBF-ß and Vif, and, therefore, which ones can prevent the degradation of APOBEC3G.

"Understanding these interactions is essential to the intelligent design of drugs that can fight HIV," continued Evans. "If we can stop Vif from degrading APOBEC3G, HIV would be severely crippled."



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Positively Aware. It is a part of the publication Positively Aware. Visit Positively Aware's website to find out more about the publication.
 
See Also
More HIV Research News

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement